Since 2019, the European Society of Cardiology included Sodium-glucose co-transporter 2 (SGLT2-inhibitors) in the ESC Clinical Practice guidelines, based on new evidence that SGLT2-inhibitors benefit patients with cardiovascular diseases and reduce the risk of cardiovascular mortality [34, 35]. The gene discussed is SLC5A2; the disease is cardiovascular disorder.